We also analyzed the relationship between ADH1B and survival in each cancer type and observed that ADH1B might increase the mortality risk in patients with lung squamous cell carcinoma (LUSC), stomach adenocarcinoma (STAD), and kidney renal papillary cell carcinoma (KIRP) (Supplementary Figure S1B). Here, ADH1B is linked to cancer.